Clene Inc. (CLNN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 27 | 81 | 87 | 91 |
| Research and development | 3,514 | 1,481 | 4,471 | 4,150 |
| General and administrative | 2,377 | 2,656 | 3,413 | 3,314 |
| Cost of revenue | - | 20 | 18 | 18 |
| Total operating expenses | 5,891 | 4,157 | 7,902 | 7,482 |
| Loss from operations | -5,864 | -4,076 | -7,815 | -7,391 |
| Change in fair value of derivative liabilities | -439 | 1,147 | - | - |
| Interest income | 62 | 81 | 127 | 269 |
| Interest expense | 679 | 608 | 1,022 | 1,282 |
| Research and development tax credits and unrestricted grants | 16 | 195 | 27 | 26 |
| Change in fair value of common stock warrant liabilities | 515 | -2,510 | -697 | -1,568 |
| Change in fair value of initial stockholders contingent earn-out liability | - | - | - | 3 |
| Change in fair value of clene nanomedicine contingent earn-out liability | - | - | - | 22 |
| Total other income (expense), net | -1,555 | 3,325 | -171 | 606 |
| Net loss before income taxes | -7,419 | -751 | -7,986 | -6,785 |
| Income tax expense | - | - | - | - |
| Net loss | -7,419 | -751 | -7,986 | -6,785 |
| Unrealized gain (loss) on available-for-sale securities | - | - | 1 | 2 |
| Unrealized loss on available-for-sale securities | - | - | - | - |
| Foreign currency translation adjustments | 63 | 15 | 52 | 28 |
| Total other comprehensive income (loss) | 63 | 15 | 53 | 30 |
| Comprehensive loss | -7,356 | -736 | -7,933 | -6,755 |
| Net loss per share basic and diluted (in dollars per share) | -0.78 | -0.09 | -1.22 | -1.06 |
| Weighted average common shares used to compute basic and diluted net loss per share (in shares) | 9,523,592 | 8,824,673 | 6,557,839 | 6,423,182 |